JP2019108366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019108366A5 JP2019108366A5 JP2019038349A JP2019038349A JP2019108366A5 JP 2019108366 A5 JP2019108366 A5 JP 2019108366A5 JP 2019038349 A JP2019038349 A JP 2019038349A JP 2019038349 A JP2019038349 A JP 2019038349A JP 2019108366 A5 JP2019108366 A5 JP 2019108366A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- compound
- formula
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 239000002270 dispersing agent Substances 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 238000007922 dissolution test Methods 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- ZFHQRKNHABBCOO-MONFIQOXSA-N (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide trihydrate Chemical compound O.O.O.C[C@@H]1[C@@H](C[C@@H](C(N1CC(F)(F)F)=O)NC(=O)C=1C=C2C(=NC1)C[C@]1(C2)C(NC2=NC=CC=C21)=O)C2=CC=CC=C2 ZFHQRKNHABBCOO-MONFIQOXSA-N 0.000 claims 1
- DDOOFTLHJSMHLN-ZQHRPCGSSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=CC=CC=C1 DDOOFTLHJSMHLN-ZQHRPCGSSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical group CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936019P | 2014-02-05 | 2014-02-05 | |
| US61/936,019 | 2014-02-05 | ||
| US201462087366P | 2014-12-04 | 2014-12-04 | |
| US62/087,366 | 2014-12-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548023A Division JP6491669B2 (ja) | 2014-02-05 | 2015-01-30 | Ｃｇｒｐ活性化合物の錠剤製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019108366A JP2019108366A (ja) | 2019-07-04 |
| JP2019108366A5 true JP2019108366A5 (enExample) | 2019-11-21 |
| JP6666490B2 JP6666490B2 (ja) | 2020-03-13 |
Family
ID=53778348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548023A Active JP6491669B2 (ja) | 2014-02-05 | 2015-01-30 | Ｃｇｒｐ活性化合物の錠剤製剤 |
| JP2019038349A Active JP6666490B2 (ja) | 2014-02-05 | 2019-03-04 | Ｃｇｒｐ活性化合物の錠剤製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548023A Active JP6491669B2 (ja) | 2014-02-05 | 2015-01-30 | Ｃｇｒｐ活性化合物の錠剤製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10117836B2 (enExample) |
| EP (1) | EP3102564A4 (enExample) |
| JP (2) | JP6491669B2 (enExample) |
| KR (3) | KR20220136460A (enExample) |
| CN (2) | CN112022818A (enExample) |
| AU (5) | AU2015214502B2 (enExample) |
| CA (1) | CA2937315A1 (enExample) |
| HK (1) | HK1232218A1 (enExample) |
| IL (1) | IL246828B (enExample) |
| MX (2) | MX383378B (enExample) |
| RU (2) | RU2019123406A (enExample) |
| SA (1) | SA516371613B1 (enExample) |
| WO (1) | WO2015119848A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI522355B (zh) * | 2010-11-12 | 2016-02-21 | 默沙東藥廠 | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| EP3102564A4 (en) | 2014-02-05 | 2017-10-18 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
| CN105126111A (zh) * | 2015-09-30 | 2015-12-09 | 清华大学 | 提高索拉非尼生物利用度的制剂 |
| IL301979B2 (en) * | 2017-03-30 | 2024-05-01 | Merck Patent Gmbh | Spray dried solid dispersions comprising (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol and their preparation |
| JP2021519288A (ja) * | 2018-03-25 | 2021-08-10 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． | Ｃｇｒｐ関連障害のためのリメゲパント |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| RU2755571C1 (ru) * | 2020-06-09 | 2021-09-17 | Сергей Геннадьевич Каплунов | Способ изготовления гравюры на металле |
| EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals International Limited | MIGRAINE TREATMENT |
| CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
| IL302948A (en) * | 2020-11-19 | 2023-07-01 | Pfizer Ireland Pharmaceuticals | Compositions for improved delivery of cgrp inhibitors |
| AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CA3206675A1 (en) * | 2021-02-02 | 2022-08-11 | Markus Von Raumer | A crystalline form of (4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(r)-3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanone |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| DE3612212A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
| TW486370B (en) | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
| US6103260A (en) * | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
| US20040076668A1 (en) | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
| US7205293B2 (en) | 2003-03-14 | 2007-04-17 | Merck & Co., Inc. | Benodiazepine spirohydantoin CGRP receptor antagonists |
| AU2004222378B2 (en) | 2003-03-14 | 2008-08-14 | Merck Sharp & Dohme Corp. | Carboxamide spirohydantoin CGRP receptor antagonists |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| ATE464305T1 (de) | 2004-09-13 | 2010-04-15 | Merck Sharp & Dohme | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| DE102004063755A1 (de) * | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
| CA2599925A1 (en) | 2005-03-14 | 2006-09-21 | Merck & Co., Inc. | Cgrp receptor antagonists |
| AU2007212197B2 (en) * | 2006-02-09 | 2012-12-13 | Merck Sharp & Dohme Corp. | Polymer formulations of CETP inhibitors |
| BRPI0711352A2 (pt) | 2006-05-09 | 2011-09-27 | Merck & Co Inc | composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular |
| EP2161996B1 (en) | 2007-06-05 | 2014-07-16 | Merck Sharp & Dohme Corp. | Heterocyclic carboxamide cgrp receptor antagonists |
| US8450327B2 (en) | 2007-10-18 | 2013-05-28 | Boehringer Ingelheim International Gmbh | CGRP antagonists |
| WO2009065922A2 (de) | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | Organische verbindungen |
| WO2009100090A1 (en) * | 2008-02-05 | 2009-08-13 | Merck & Co., Inc. | Prodrugs of cgrp receptor antagonist |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| CN104983701A (zh) | 2008-04-15 | 2015-10-21 | 默沙东公司 | 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物 |
| DK3222277T3 (da) * | 2009-03-31 | 2020-05-11 | Ligand Pharm Inc | Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati |
| US8765763B2 (en) | 2009-06-05 | 2014-07-01 | Boehringer Ingelheim International Gmbh | Substituted piperazines as CGRP antagonists |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| WO2012064911A1 (en) | 2010-11-12 | 2012-05-18 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide indane cgrp receptor antagonists |
| TWI522355B (zh) | 2010-11-12 | 2016-02-21 | 默沙東藥廠 | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| WO2012087777A1 (en) | 2010-12-22 | 2012-06-28 | Merck Sharp & Dohme Corp. | Fused heterocyclic indane carboxamide cgrp receptor antagonists |
| US9067941B2 (en) | 2010-12-22 | 2015-06-30 | Merck Sharp & Dohme Corp. | Fused heterocyclic azaindane carboxamide CGRP receptor antagonists |
| EP2654726A1 (en) * | 2011-03-08 | 2013-10-30 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| EP2685826B1 (en) | 2011-03-18 | 2016-02-03 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
| US9109209B2 (en) | 2011-09-08 | 2015-08-18 | Codexis, Inc. | Biocatalysts and methods for the synthesis of substituted lactams |
| DK2765990T3 (da) | 2011-10-14 | 2017-11-13 | Array Biopharma Inc | Faststofdispersion |
| US9487523B2 (en) | 2012-03-14 | 2016-11-08 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| AU2013232191B2 (en) | 2012-03-14 | 2017-03-30 | Merck Sharp & Dohme Llc | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
| CN104411295B (zh) | 2012-04-25 | 2017-10-10 | 伊诺威斯药物公司 | 敏感化组合物和使用方法 |
| US9227973B2 (en) | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyridine CGRP receptor antagonists |
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| EP2846799B1 (en) | 2012-05-09 | 2017-11-15 | Merck Sharp & Dohme Corp. | Spirolactam cgrp receptor antagonists |
| WO2013169574A2 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam cgrp receptor antagonists |
| NZ747040A (en) | 2013-03-15 | 2020-02-28 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| RU2690006C2 (ru) | 2013-09-16 | 2019-05-30 | Мерк Шарп И Доум Корп. | Композиции антагонистов рецепторов cgrp |
| US20160346198A1 (en) | 2014-02-05 | 2016-12-01 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| EP3102564A4 (en) | 2014-02-05 | 2017-10-18 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
| EP3110427A4 (en) | 2014-02-24 | 2018-05-30 | Urigen Pharmaceuticals, Inc. | Compositions of pentosan polysulfate salts for oral administration and methods of use |
| AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
| JP6673924B2 (ja) | 2015-01-23 | 2020-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
| EA201890578A1 (ru) | 2015-09-24 | 2018-12-28 | Тева Фармасьютикалз Интернэшнл Гмбх | Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли |
| US20180092899A1 (en) | 2016-09-30 | 2018-04-05 | Merck Sharp & Dohme Corp. | Method of treating acute migraine with cgrp-active compound |
| CN110621343A (zh) | 2017-03-02 | 2019-12-27 | 贝丝以色列女执事医疗中心 | 选择对针对降钙素基因相关肽的抗体有反应的头痛患者 |
| TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| US20190135927A1 (en) | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
| US20190374520A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20190374518A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| CA3133912A1 (en) | 2019-04-18 | 2020-10-22 | Allergan Sales, Llc | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| AU2020355233A1 (en) | 2019-09-25 | 2022-05-19 | Allergan Pharmaceuticals International Limited | Combination therapy with CGRP antagonists |
| EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals International Limited | MIGRAINE TREATMENT |
| AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
-
2015
- 2015-01-30 EP EP15746768.9A patent/EP3102564A4/en active Pending
- 2015-01-30 AU AU2015214502A patent/AU2015214502B2/en active Active
- 2015-01-30 RU RU2019123406A patent/RU2019123406A/ru unknown
- 2015-01-30 JP JP2016548023A patent/JP6491669B2/ja active Active
- 2015-01-30 CN CN202010812438.5A patent/CN112022818A/zh active Pending
- 2015-01-30 KR KR1020227032939A patent/KR20220136460A/ko not_active Ceased
- 2015-01-30 HK HK17105813.5A patent/HK1232218A1/zh unknown
- 2015-01-30 WO PCT/US2015/013672 patent/WO2015119848A1/en not_active Ceased
- 2015-01-30 CN CN201580006288.6A patent/CN105960397B/zh active Active
- 2015-01-30 KR KR1020167024025A patent/KR102448369B1/ko active Active
- 2015-01-30 CA CA2937315A patent/CA2937315A1/en active Pending
- 2015-01-30 MX MX2016010169A patent/MX383378B/es unknown
- 2015-01-30 US US15/115,026 patent/US10117836B2/en active Active
- 2015-01-30 KR KR1020237022803A patent/KR20230107902A/ko not_active Ceased
- 2015-01-30 RU RU2016135536A patent/RU2696578C1/ru active
-
2016
- 2016-07-18 IL IL246828A patent/IL246828B/en active IP Right Grant
- 2016-08-04 SA SA516371613A patent/SA516371613B1/ar unknown
- 2016-08-04 MX MX2021006790A patent/MX2021006790A/es unknown
-
2018
- 2018-11-02 US US16/178,641 patent/US20190209478A1/en not_active Abandoned
-
2019
- 2019-03-04 JP JP2019038349A patent/JP6666490B2/ja active Active
- 2019-09-06 AU AU2019226239A patent/AU2019226239B2/en active Active
-
2020
- 2020-12-03 US US17/110,398 patent/US11925709B2/en active Active
-
2021
- 2021-10-08 AU AU2021245229A patent/AU2021245229A1/en not_active Abandoned
-
2023
- 2023-04-21 US US18/137,925 patent/US20230248655A1/en not_active Abandoned
- 2023-10-30 AU AU2023258317A patent/AU2023258317A1/en not_active Abandoned
-
2025
- 2025-08-22 AU AU2025220825A patent/AU2025220825A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1163223C (zh) | 肠内目标部位释放型制剂 | |
| JP2986546B2 (ja) | スマトリプタンを含有する組成物 | |
| ES2337935T3 (es) | Comprimidos de accion retardada con hidromorfona. | |
| JPH09143073A (ja) | 持続性ニフエジピン製剤 | |
| TW200301139A (en) | Zero-order sustained release dosage forms and method of making same | |
| JP5948648B2 (ja) | 安定化されたエペリゾンを含有する徐放性製剤 | |
| WO2010103544A2 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| WO2006082523A2 (en) | Pharmaceutical sustained release composition of metformin | |
| JP6768070B2 (ja) | 粘膜付着性医薬組成物及びその製造方法 | |
| CN107205950B (zh) | 金刚烷胺组合物的施用方法 | |
| TW201113050A (en) | 3-cyanoquinoline tablet formulations and uses thereof | |
| CN101854929A (zh) | 新型制剂 | |
| WO2018108157A1 (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| BR112015010271B1 (pt) | produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos | |
| Aslam et al. | Techniques and polymers used to design Gastroretentive drug delivery systems–a review | |
| CN101011393B (zh) | 厄贝沙坦胃内滞留型缓释药物组合物 | |
| ES2899885T3 (es) | Nueva composición farmacéutica de liberación diferencial que contiene tres principios activos | |
| JP2025078766A (ja) | ピリミジニルアミノピラゾール化合物の調節放出製剤および処置方法 | |
| JPS61286330A (ja) | 経口徐放性製剤 | |
| JP5919173B2 (ja) | 徐放性塩酸アンブロキソール口腔内崩壊錠 | |
| JP3007387B2 (ja) | 徐放性製剤用基剤粉末 | |
| CN107249569A (zh) | 一种包含含有盐酸坦索罗辛的缓释颗粒的口服药物制剂 | |
| WO2009076754A1 (en) | Single layered controlled release therapeutic system | |
| CN1440278A (zh) | 2′－脱氧－2′－(氟亚甲基)胞嘧啶核苷的药物组合物 | |
| WO2013051036A1 (en) | Use of pharmaceutical composition for gastroretentive sustained and pulsatile drug delivery system |